title: Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation.
abstract: The objective of this study was to apply a one-step melt granulation method to develop an extended-release formulation of lovastatin (LOV-ER). We prepared a formulation using PEG 6000 as binder agent in a laboratory scale high-shear mixer. In vitro dissolution studies showed that the release of the drug from the new formulation followed a zero-order kinetic with no differences in the release profile with either the pH media or the agitation rate. The pharmacokinetic of lovastatin and its metabolite lovastatin acid was evaluated after the administration of the new formulation to Beagle dogs in fasted conditions and after a high-fat meal, and compared to the marketed formulation Altoprev®. After the administration of LOV-ER, extended plasma profiles of lovastatin and its active metabolite were achieved in both fasted conditions and after the high-fat meal. Plasma levels of lovastatin and lovastatin acid were always higher when the LOV-ER formulation was administered with the high-fat meal. A high variability in plasma levels and pharmacokinetic parameters was obtained, being this variability higher when the formulation was administered under fasting conditions. Our results suggest that there is an increase in lovastatin bioavailability when the formulation is administered after the high-fat meal. When we compare LOV-ER and Altoprev®, both administered after the high-fat meal, we found significant differences (p<0.05) in C(max) of lovastatin and in AUC(0-∞) and MRT of lovastatin acid. No differences were detected between both formulations in fasting conditions. In this regard, the high-fat meal seems to increase the absorption extent of lovastatin from LOV-ER formulation and to delay the absorption rate of the drug from Altoprev®. In conclusion, we developed a lovastatin formulation that provided extended plasma levels that confirm that one-step melt granulation in high-shear mixer could be an easy and cost-effective technique for extended-release formulation development.
authors.affiliation: Laboratory of Pharmacy and Pharmaceutical Technology, University of the Basque Country (UPV-EHU), Vitoria-Gasteiz, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Ochoa
authors.forename: M
authors.initials: M
authors.lastname: Igartua
authors.forename: R M
authors.initials: RM
authors.lastname: Hernández
authors.forename: A R
authors.initials: AR
authors.lastname: Gascón
authors.forename: M A
authors.initials: MA
authors.lastname: Solinis
authors.forename: J L
authors.initials: JL
authors.lastname: Pedraz
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics; D019540:Area Under Curve; D003692:Delayed-Action Preparations; D004285:Dogs; D004339:Drug Compounding / Q000379:methods*; D005079:Excipients; D006358:Hot Temperature; D057927:Hydrophobic and Hydrophilic Interactions; D008148:Lovastatin / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics; D011092:Polyethylene Glycols; D012995:Solubility
chemical_list: D000924:Anticholesteremic Agents; D003692:Delayed-Action Preparations; D005079:Excipients; D011092:Polyethylene Glycols; D008148:Lovastatin